Is fetal growth restriction caused by failure of the placenta to adapt to nutrient demand?

In this study we will compare placentas from normal and Fetal Growth Restricted-affected pregnancies to identify what the important signals might be.

  • Authors list

    Dr Christina Hayward, Kirsty McIntyre, Dr Susan Greenwood, Dr Paul Brownbill, Dr Richard Unwin, Professor Colin Sibley, Dr Mark Dilworth

Babies that don’t grow as expected are at greater risk of being stillborn. Should these babies survive, they are then at a greater risk of disability in childhood, such as cerebral palsy or developmental delay. There are now well-defined links between being born small, termed fetal growth restriction (FGR), and an increased risk of diseases. Thus, FGR is responsible for a significant emotional and financial burden on families and the NHS, both before and after birth. 

For the growth of the baby to proceed as normal, a placenta that functions as normal is crucial. If the placenta fails to function, fetal growth restriction (FGR) may occur. 

Evidence suggests that in normal pregnancies, the baby is able to signal to the mother to alter the amount of nutrients getting across, via the placenta. In FGR, there is evidence that this signalling between baby and mother fails. This means that the transfer of nutrients by the placenta is insufficient for normal growth and FGR occurs.This study aims to examine the signals that baby produces in more detail. In the study we will compare placentas from normal and FGR-affected pregnancies to identify what these important signals might be. This includes using cutting-edge technologies to identify key markers within umbilical cord blood (which flows from the baby to the placenta) and the baby’s side of the placenta (where these signals would act). We can then test these signals in placentas after delivery of the baby to determine whether they alter placental transfer of nutrients in a way that would be beneficial for the baby. 

Get our research updates

Tommy's funds research across the UK investigating the reasons for pregnancy complications and loss. We can keep you updated on our research news.  If you're interested in being kept updated about our research and news from Tommy's, click here.

Read more on this topic

  • Research into stillbirth

    When a baby dies after 24 weeks of gestation, it is called a stillbirth. Nearly 3000 families a year get the devastating news that their baby is not alive. Our research is helping to change this.
    Research into stillbirth

  • Preventing stillbirth: the role of the immune system in rejecting the placenta

    Tommy’s are studying chronic histiocytic intervillositis, which causes the immune system to reject the placenta, leading to stillbirth or miscarriage.
    Preventing stillbirth: the role of the immune system in rejecting the placenta

  • Understanding how the womb lining matures during pre-eclampsia

    Pre-eclampsia can lead to health problems and sometimes stillbirth, but we don’t know enough about what causes it. Our researchers are studying how the lining of the womb develops during early pregnancy. This could reveal new ways to prevent pre-eclampsia and reduce the risk of stillbirth.
    Understanding how the womb lining matures during pre-eclampsia

  • The AFFIRM trial for prevention of stillbirth

    Researchers supported by Tommy’s are looking at whether a package of care and resources for pregnant women can help stop stillbirths.
    The AFFIRM trial for prevention of stillbirth

  • Homing peptides: targeting drugs to the placenta

    Drugs which could help prevent pregnancy complications can’t reach the placenta effectively. Tommy’s researchers are making use of ‘homing peptides’ to deliver drugs directly to the placenta. This work could help to prevent pregnancy complications and stillbirth.
    Homing peptides: targeting drugs to the placenta

  • Stillbirth and fetal free haemoglobin

    Researchers supported by Tommy’s have found that the substance that usually carries oxygen around our blood may have harmful effects on the baby when it escapes from red blood cells.
    Stillbirth and fetal free haemoglobin

  • Diabetes, fetal growth and stillbirth

    Women suffering from type 1 or type 2 diabetes are more likely to suffer from stillbirths. We want to help people with diabetes to have healthy pregnancies.
    Diabetes, fetal growth and stillbirth

  • ReMIT-2 – a feasibility study for spotting the early signs of complications

    We need better ways to spot the early signs of pregnancy complications. The ReMIT-2 study laid the foundations for a large clinical trial of a blood test which could predict which women need urgent care to prevent stillbirth.
    ReMIT-2 – a feasibility study for spotting the early signs of complications

  • Can low levels of taurine make stillbirth more likely?

    Tommy’s researchers are looking at how the lack of an important nutrient might harm the placenta during pregnancy, putting women at a higher risk of stillbirth.
    Can low levels of taurine make stillbirth more likely?

  • Older mothers and the ageing placenta

    Consistent with ageing, the placenta in older mothers does not work as effectively. Researchers supported by Tommy’s are investigating why this happens.
    Older mothers and the ageing placenta

  • Can steroid injections improve blood flow to babies at risk of stillbirth?

    Finding out whether steroids can improve the blood flow through the placenta
    Can steroid injections improve blood flow to babies at risk of stillbirth?

  • Older mothers and the risk of stillbirth

    Women over 35 are more likely to have a stillbirth. Researchers supported by Tommy’s are looking at how the placenta may play a role in this, and are testing how we can stop stillbirths by making sure the placenta is healthy.
    Older mothers and the risk of stillbirth